S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
The Day of Financial Reckoning Is Near (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
The Day of Financial Reckoning Is Near (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
The Day of Financial Reckoning Is Near (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
The Day of Financial Reckoning Is Near (Ad)
NASDAQ:FRLN

Freeline Therapeutics - FRLN Stock Forecast, Price & News

$0.95
-0.01 (-1.04%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.90
$0.96
50-Day Range
$0.72
$1.10
52-Week Range
$0.65
$4.25
Volume
26,879 shs
Average Volume
127,639 shs
Market Capitalization
$59.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.75

Freeline Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
1,031.6% Upside
$10.75 Price Target
Short Interest
Healthy
0.37% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.22mentions of Freeline Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.83) to ($1.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

483rd out of 1,135 stocks

Biological Products, Except Diagnostic Industry

68th out of 180 stocks

FRLN stock logo

About Freeline Therapeutics (NASDAQ:FRLN) Stock

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Wall Street Analysts Forecast Growth

Separately, BTIG Research lowered their price objective on shares of Freeline Therapeutics from $10.00 to $5.00 and set a "buy" rating for the company in a research report on Thursday. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $10.75.

Freeline Therapeutics Stock Performance

NASDAQ:FRLN traded down $0.01 during trading on Friday, hitting $0.95. The stock had a trading volume of 26,879 shares, compared to its average volume of 127,639. The company has a market capitalization of $59.23 million, a PE ratio of -0.34 and a beta of 0.01. Freeline Therapeutics has a 12 month low of $0.65 and a 12 month high of $4.25. The company's 50-day moving average price is $0.87 and its two-hundred day moving average price is $0.95.

Freeline Therapeutics (NASDAQ:FRLN - Get Rating) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.05). As a group, equities analysts anticipate that Freeline Therapeutics will post -1.83 earnings per share for the current fiscal year.

Receive FRLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Freeline Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FRLN Stock News Headlines

Freeline picks industry veteran for CFO role
See More Headlines
Receive FRLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Freeline Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FRLN Company Calendar

Last Earnings
11/09/2021
Today
8/14/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FRLN
Fax
N/A
Employees
236
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.75
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+1,031.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

Net Income
$-140,390,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.44 per share

Miscellaneous

Free Float
N/A
Market Cap
$59.23 million
Optionable
Not Optionable
Beta
0.01

Key Executives

  • Mr. Michael J. Parini J.D. (Age 47)
    CEO, COO, Pres & Exec. Director
    Comp: $1.13M
  • Dr. Amit Chunilal Nathwani M.D. (Age 62)
    Ph.D., Founder, Independent Clinical & Scientific Advisor and Director
    Comp: $513k
  • Dr. Markus Horer Ph.D. (Age 55)
    Founder, CTO & Managing Director GmbH
  • Mr. Mark Baldry M.B.A. (Age 58)
    Chief Commercial Officer
  • Mr. James Bircher (Age 53)
    Chief Technical Operations Officer
  • Dr. Pamela Foulds M.D. (Age 52)
    Chief Medical Officer
  • Mr. Paul M. Schneider
    Chief Financial Officer
  • Dr. Henning R. Stennicke Ph.D. (Age 54)
    Chief Scientific Officer
  • Arne Naeveke Ph.D.
    VP & Head of Corp. Communications
  • Ms. Nicole Jones SPHR
    Chief People Officer













FRLN Stock - Frequently Asked Questions

Should I buy or sell Freeline Therapeutics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Freeline Therapeutics in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FRLN shares.
View FRLN analyst ratings
or view top-rated stocks.

What is Freeline Therapeutics' stock price forecast for 2022?

8 equities research analysts have issued 12-month price targets for Freeline Therapeutics' shares. Their FRLN share price forecasts range from $5.00 to $20.00. On average, they predict the company's share price to reach $10.75 in the next year. This suggests a possible upside of 1,031.6% from the stock's current price.
View analysts price targets for FRLN
or view top-rated stocks among Wall Street analysts.

How have FRLN shares performed in 2022?

Freeline Therapeutics' stock was trading at $1.98 at the beginning of the year. Since then, FRLN shares have decreased by 52.0% and is now trading at $0.95.
View the best growth stocks for 2022 here
.

When is Freeline Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our FRLN earnings forecast
.

How were Freeline Therapeutics' earnings last quarter?

Freeline Therapeutics Holdings plc (NASDAQ:FRLN) announced its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.86) EPS for the quarter, beating the consensus estimate of ($1.01) by $0.15.

What other stocks do shareholders of Freeline Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Freeline Therapeutics investors own include Adobe (ADBE), BigCommerce (BIGC), Checkmate Pharmaceuticals (CMPI), CVS Health (CVS), Old Dominion Freight Line (ODFL), Oak Street Health (OSH), Rocket Companies (RKT), Shopify (SHOP), Zoom Video Communications (ZM) and Zymeworks (ZYME).

When did Freeline Therapeutics IPO?

(FRLN) raised $126 million in an initial public offering (IPO) on Friday, August 7th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Morgan Stanley and Evercore ISI served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Freeline Therapeutics' stock symbol?

Freeline Therapeutics trades on the NASDAQ under the ticker symbol "FRLN."

Who are Freeline Therapeutics' major shareholders?

Freeline Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.43%).

How do I buy shares of Freeline Therapeutics?

Shares of FRLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Freeline Therapeutics' stock price today?

One share of FRLN stock can currently be purchased for approximately $0.95.

How much money does Freeline Therapeutics make?

Freeline Therapeutics (NASDAQ:FRLN) has a market capitalization of $59.23 million. The company earns $-140,390,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis.

How many employees does Freeline Therapeutics have?

The company employs 236 workers across the globe.

How can I contact Freeline Therapeutics?

Freeline Therapeutics' mailing address is STEVENAGE BIOSCIENCE CATALYST GUNNELS WOOD ROAD STEVENAGE, HERTFORDSHIRE X0, SG12FX. The official website for the company is www.freeline.life. The company can be reached via phone at 44-0-14-3890-6870 or via email at ir@freeline.life.

This page (NASDAQ:FRLN) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.